When Kai Raydon, a neuropharmacology student at the University of Colorado Boulder, ordered a package through the dark web in the summer of 2023, he had no idea he was about to become another casualty of novel synthetic drugs. He tested the orange-white powder for fentanyl. The strip came back negative. After inhaling a gram of the substance, he messaged a friend: “Just tried the ludes and they are just as good as people say.”

By the following morning, he was dead.

The powder was not the sedative he had ordered. It turned out to be N-desethyl etonitazene, a novel synthetic drug from a family of compounds called nitazenes, reported to be ten times more potent than fentanyl. His girlfriend, Emma Buck, found him in bed with his rat terrier perched on top of him, and only realised something was wrong when she felt his cold body.

Kai’s story is not an isolated tragedy. It opens a window into one of the most dangerous and least understood shifts in the modern drugs landscape.

A Novel Synthetic Drug Supply That Nobody Can Map

The scale of the problem is staggering. In 1971, 6,771 Americans died of a drug overdose. By 2024, that figure had reached 80,000, nearly a 70 per cent increase from a decade earlier. The driving force behind this rise is not any single substance. It is the explosive spread of novel synthetic drugs that emerge faster than authorities can identify, classify or respond to them.

The United Nations Office on Drugs and Crime currently lists 1,446 new psychoactive substances, up from 643 a decade ago. Unlike traditional street drugs, these are lab-engineered compounds. Illicit manufacturers produce them in unregulated facilities across China, India and Mexico, then sell them through encrypted online marketplaces before health agencies have any idea they exist.

A recent study from the National Institute of Standards and Technology found that 42 per cent of drug samples containing fentanyl now include five or more psychoactive compounds, up from 23 per cent just three years ago. Edward Sisco, a research chemist at the institute, put it plainly: “You have almost no chance of knowing what you’ve got.”

The Internet as a Cookbook for New Psychoactive Substances

Access to scientific knowledge has fundamentally changed the landscape of illicit drug manufacturing. Dr Laura Bohn, an associate dean of research at the Morsani College of Medicine at the University of South Florida, describes the internet as the “cookbook” for the drug trade.

Virtually any molecular structure or chemistry study published in an academic journal is now immediately available to amateur chemists and illicit suppliers worldwide. Most novel synthetic drugs begin life in legitimate medical research, then get copied and modified by clandestine chemists with no obligation to test for safety, accurate dosage or purity.

Nitazenes are a clear example of how this works. The drug family was first developed in the late 1950s by Swiss pharmaceutical company Ciba, whose scientists hoped it might become a pain medication. Early trials showed the compounds dangerously suppressed breathing, so the project was abandoned. The chemical structures sat largely forgotten in old German patents for decades.

Then, in 2019, a fatality in Alberta, Canada, was linked to isottonitazene, a nitazene variant. Further deaths followed in Minnesota, Iowa and other states. Forensic toxicologists began to suspect that illicit manufacturers, facing crackdowns on fentanyl in both the US and China, had gone mining through historical pharmaceutical literature for replacements.

Predicting the Future, or Creating It?

Scientists responded to the emerging nitazene threat with what experts call “prophetic” research: attempting to model which new psychoactive substances might appear on the streets before they actually did. The goal was to give hospitals, law enforcement agencies and public health bodies enough time to prepare.

In March 2021, two related papers appeared in ACS Chemical Neuroscience. Hungarian medicinal chemist Dr István Ujváry co-authored the first alongside senior officials from the European Union Drugs Agency. Together they reviewed decades of nitazene research and examined how the molecules could be modified. The second paper modelled hypothetical new compounds and explored how they would interact with the brain’s opioid receptors.

Not long after publication, some of the drugs discussed in those papers began appearing in real-world overdose cases. By 2023, one of the hypothetical compounds from the second paper, N-desethyl etonitazene, had become a reality on the streets. It was the novel synthetic drug that killed Kai Raydon.

When Science Becomes a Blueprint

That sequence of events raised an uncomfortable question. At a Philadelphia symposium in November 2024, Simon Elliott, a visiting professor in forensic toxicology at King’s College London, put it directly to the assembled researchers: “Is there a chance you actually start the trend?”

Dr Alex Krotulski, who runs the Centre for Forensic Science Research and Education in Pennsylvania, the lab that identified the compound in Raydon’s blood, was candid. “The reality is, yes, there’s always a possibility,” he said. “Nobody knows what’s really coming next. So you can make the argument that having that information is more beneficial to us than not having the information.”

Dr Ujváry was equally direct. “If I can access the literature, then they also can find those structures,” he said. Staying ahead of illicit chemists, he argued, was the only real option.

Unidentified, Uncounted and Uncontrolled

The forensic challenge alone is immense. In 2023, the Centre for Forensic Science Research and Education handled 268 cases involving unidentified novel drug substances. The centre is now on pace to exceed 1,000 such cases in a single year by 2026, nearly a fourfold increase in just three years.

Kai Raydon’s biological samples arrived at the laboratory in October 2023. Scientists ran them through a high-resolution mass spectrometer and checked the results against a database of 1,200 known drug molecules. A match was not found until November. For families waiting on answers after a loved one’s death, that kind of timeline means weeks of anguish.

Katie Becker, a morgue supervisor for Boulder County who assisted in the autopsy, initially described the cause of death as a “mystery.” Foam around the lips pointed to opiate overdose, yet standard toxicology screens found no fentanyl. Raydon’s case is a preview of what more families are beginning to face as new psychoactive substances proliferate.

What Novel Synthetic Drugs Mean for Families and Communities

Kai Raydon’s case illustrates something statistics alone cannot convey. He was, by all accounts, careful and intellectually curious. He tested his purchase before using it and believed he was making an informed choice. Even so, he could not have known what he was really dealing with. No widely available test existed for the substance that ended his life.

Novel synthetic drugs and new psychoactive substances have shifted the risk in ways that even experienced users cannot navigate. Compounds are mixed, substituted and adulterated at a pace that outstrips any individual’s ability to protect themselves, and it stretches public health infrastructure to its limits.

The science of prophetic toxicology, the work of people like Dr Krotulski and Dr Ujváry, represents a genuine effort to stay ahead. But as their own words make clear, the race is far from won. Every new compound identified has, in too many cases, already left a trail of preventable deaths behind it.

Source: dbrecoveryresources